Eli Lilly is investing up to 2.75 billion in Insilico Medicine’s AI platform, Pharma.AI, indicating a significant transition in the pharmaceutical sector towards AI-driven drug discovery and international research partnerships.
The notion that artificial intelligence might transform white-collar employment is well-established. It has already altered sectors from algorithmic trading on Wall Street to content creation in Hollywood. Now, it is set to impact one of the most intricate and crucial areas—drug discovery.
Continue Reading with
Continue Reading with
CNBC-TV18 Access Membership
Priority Access and Networking: CNBC-TV18’s flagship events
Engagement with CNBC-TV18’s journalists
Webinars & LIVE Q&As with leaders from India Inc.
Exclusive tours of CNBC-TV18’s studio & newsroom
Premium insights, expert opinions & analyses
Curated lifestyle privileges & offers
